by deficiency in endoglin, an angiogenic protein. The net effect of endoglin expression on cancer outcomes from animal studies has proven controversial. We evaluated whether reduced systemic endoglin levels, expected in patients diagnosed with HHT, impacted clinical outcomes for cancer.
Introduction
While tremendous advances in cancer treatment have occurred in recent years, new therapies are needed for tumors that do not respond to standard treatment or that acquire resistance. Endoglin is required for angiogenesis (1) (2) (3) , and shows promise as a therapeutic target in cancer treatment. Early phase clinical trials of anti-endoglin therapy (4) suggest efficacy, but the basic mechanisms of endoglin targeting affecting cancer progression remain poorly understood. Most of our knowledge of endoglin and cancer progression has been gained from cell and animal studies, but another potential source of information is from the study of patients with a rare genetic disorder that results in a natural deficiency of endoglin, occurring with hereditary hemorrhagic telangiectasia (HHT).
Current studies of endoglin and cancer progression. Endoglin is a transmembrane
glycoprotein that interacts with the transforming growth factor-beta (TGFβ) receptors (5), including ALK1 (ACVRL1) (6) , and modulates TGFβ and bone morphogenetic protein (BMP) signaling. (7) It is normally expressed in endothelial cells of the developing vasculature where it is required for angiogenesis (1, 3, 8) . Endoglin is a prognostic marker for a variety of malignancies (9) (10) (11) , likely reflecting the degree of tumor angiogenesis. These include prostate (12, 13) , breast (14), lung (15) , and colon (16) cancers (reviewed in (17, 18) ).
Studies using human prostate cancer cell line xenograft models demonstrate that overexpression of endoglin in prostate cancer cells inhibits tumor cell invasion (19) and metastasis (20) (21) (22) . This suggests that sustained expression of tumor-associated endoglin might provide a plausible strategy to inhibit metastasis. However, data obtained using an autochthonous mouse model of prostate cancer indicates that endoglin is required for the support of prostate tumors by cancer-associated myofibroblasts, promoting tumor vascularization and subsequent progression to metastatic disease (23) including the validity of the survival outcomes, is described elsewhere (31).
Informed Consent:
The Institutional Review Board of Maine Medical Center approved this study. All patient data within the SEER-Medicare data set are based on registry data and are de-identified. Thus, it was not possible to seek informed consent from each participant, and we received a Waiver of Consent. Cohort Definition. We identified patients who were diagnosed with breast, colorectal, lung, or prostate cancer between 2000 and 2007. Patients were included if they were continuously enrolled as disabled or aged (65 years or older) in the fee-for-service Medicare Parts A and B for two years prior to their cancer diagnosis, with no health maintenance organization (HMO) enrollment during this time period. Continuous enrollment allowed us to capture all medical claims for these patients during this time period. We did not have access to HMO claims, thus patients seen by an HMO were excluded. Two years of eligibility rather than one was required to extend the ascertainment period for HHT. Less prevalent cancers were not evaluated due to insufficient numbers of such patients with an HHT diagnosis. We did not exclude patients based on age although less than one percent of our cohort was younger than 52 years due to the prevalence of aged rather than disabled patients in the Medicare population and the increasing incidence of cancer with age. The youngest subject was 21 years old.
Covariates. We categorized subjects into four age groups based on age at diagnosis (≤ 65, 66-69, 70-79, 80+). Race was defined as black (yes/no), and marital status as married (yes/no).
Disease stage according to the American Joint Committee on Cancer (AJCC) classification was obtained from SEER records. Comorbidities were ascertained from inpatient and physician visit claims (including Part B and Outpatient claims, (32)) for 12 months prior to the cancer diagnosis using the Deyo implementation (33) of the Charlson comorbidity score (34). We categorized subjects as HHT if they had an HHT diagnosis during the two-year ascertainment period (International Classification of Diseases 9 th Revision, Clinical Modification (ICD-9) code 448.0).
The diagnosis criteria for HHT is based on the Curaçao criteria which has recently been studied in (35) , and found to have good predictive performance, with "positive predictive value of a definite clinical diagnosis of 100% (95% CI 97.8-100)" and "negative predictive value of an unlikely diagnosis of 97.7% (95% CI 87.9-99.6)". We also recorded rates of AVMs in both HHT and non-HHT patient groups. AVMs represent a heterogeneous group of lesions comprising multiple codes. Three ICD codings were considered representative for the purposes of the present study (ICD-9 codes 747.6, 417.0, and 747.81). and unknown stage), and the presence of one or more comorbidities. For comparison we also fit the same set of models but using the raw Charlson Comorbitiy Index (CCI) rather than the dichotomized variable of one or more comorbidities. Some individual comorbidities were reported in Table 1 for descriptive purposes, but were not included individually in the survival models. Also for comparison, we fit crude Cox models with a term for HHT, to present hazards ratios with confidence intervals for both the crude models and the full (adjusted) models.
Analyses were conducted using SAS (SAS version 9.3 for Windows; SAS Institute, Cary, NC).
We tested the proportional hazards assumption for each Cox model using a previously proposed method (37, 38) in which an interaction term with a time-varying covariate was added and tested for significance. We also performed a meta-analysis of the crude and adjusted survival models across the four cancers using an inverse variance approach as implemented in the function metagen in the R package meta (39, 40) . All statistical tests were performed at a level of 0.05 unless otherwise stated. Power analyses were performed to estimate the expected power for our given sample size for a composite of the four cancers and for each cancer separately using Proc Power in SAS 9.2. We used the two sample survival option in SAS, inputting the observed median survival time for the non-HHT group and the expected survival time in the HHT group given different values of the hazard ratio.
Results

Description of Cohort
A summary of the demographic and clinical characteristics of the cohort for HHT and non-HHT patients is given in Table 1 . Our observed HHT rate was found to be 2.3 HHT subjects per 10,000, which is consistent with current estimates of prevalence in the United States (1 to 2 subjects per 10,000 people (41)). The number of HHT patients found in the Medicare claims may be higher than in the general population due to the enrichment for elderly subjects, in which HHT is better ascertained, and due to enrichment for subjects receiving medical treatment through the Medicare system. HHT may be under-ascertained in the general population for a variety of reasons, including rarer, uncharacterized mutations leading to HHT (42) .
The age distribution for HHT and non-HHT groups were roughly the same, with slightly more HHT subjects in the 70-79 range (53.5% vs. 48.4%) and slightly less in the above 80 category (24.4% vs. 31.1%; overall P value for age was 0.44). The gender distribution was roughly the same between groups. Race rates between HHT and non-HHT groups could not be reported in Table 1 due to the suppression of small cell sizes in the HHT group; however, it was found that there were significantly more black patients in the non-HHT group as compared with the HHT group. HHT patients were more represented in the higher income categories, (45.7% vs. 26.6% in the $58K plus median income category, P<0.001), and were more highly educated vs. 30.9%, P=0.008).As expected, incidence of AVMs was higher among the HHT population (10.2% vs. 1.9%, P<0.001). Finally, HHT patients show slightly higher rates of comorbid conditions, although these differences were not statistically significant.
Survival Analysis
Kaplan-Meier survival curves stratified by HHT diagnosis for a composite of the four cancers and separately by cancer are shown in Figures 1 and 2 , respectively. In the composite cancer model, patients with a diagnosis of HHT had a significantly increased survival ( Fig. 1, P <0.0001). For individual cancers, breast cancer showed the strongest association between HHT diagnosis and survival ( Fig. 2A, P=0 .0056). Prostate cancer also achieved statistical significance (Fig. 2B, P=0 .025). In contrast, though lung and colorectal cancers showed similar trends, the improvement of survival with HHT diagnosis for these cancers did not achieve statistical significance (Fig. 2C, P=0.080; Fig. 2D, P=0 .301, respectively). A power analysis showed that our study had good power (88%) to detect the observed hazard ratio of 0.7 for the HHT group for the composite adjusted model, and very high power (>99%) to detect a hazard ratio of 0.56 in the unadjusted model. For breast cancer, we had 91% power to detect a hazard ratio of 0.3 in the HHT group, which was the effect in the adjusted and unadjusted models. For prostate cancer, we had 77% power to detect the unadjusted effect size of 0.44 and only 55% power to detect the adjusted effect size of 0.56. For colorectal cancer we had less than 38% power to detect the observed effects sizes in the adjusted and prostate, colorectal, and lung cancer) in a survival analysis adjusting for confounding demographic and clinical factors. In addition, we show a particularly strong protective effect of HHT in breast cancer. While we can only hypothesize the underlying cause for the improved survival outcomes among HHT patients, we propose that impaired expression of endoglin in HHT patients contributes a benefit due to reduced stromal support and angiogenesis, which impairs tumor progression. These findings are consistent with an enhancement of TGFβ-mediated stimulation of cancer-associated fibroblasts that promote tumor invasion (44) . Thus, our study provides important insight into the existing animal model systems data that has yielded opposing results on the net effect of reduced endoglin expression, depending on the context of endoglin expression: the tumor itself versus the tumor microenvironment. For the first time, population data reflecting endoglin deficiency provide support for the hypothesis that there is a net benefit to reduced endoglin expression, thus underscoring the importance of the stromal microenvironment in specific tumor types, including breast and prostate cancers.
The strength of the present study is that it represents a large comprehensive national survey of incident cancer cases in the United States. Thus, even though HHT is a rare disorder, the study sample gave sufficient power to compare survival outcomes of cancer patients with and without a recorded diagnosis of HHT. The limitations of this study include that it is an observational study, and as such, confounding of HHT diagnosis with other clinical and demographic variables is possible. However, we have attempted to address confounding by adjusting our survival models by variables that are associated with HHT. Another limitation is that we have not recorded and adjusted for potential treatment differences in this cohort which may influence survival. While we do not expect variation in treatment to occur across these two groups (HHT and non-HHT), we have not specifically addressed this point which would be challenging to assess due to the differences in standard treatment for the four different cancers being considered, so this is a limitation of the present study. Another limitation is that the use of event-based reporting of HHT status from Medicare (billing) claims data two years prior to 
cancer diagnosis may result in undercounting HHT cases. However, we do not expect HHT reporting through claims data to be effected by differential health care coverage, as by design our cohort contains patients with Medicare coverage only (no supplementary coverage).
In conclusion, this is a retrospective study that includes a large representative sample of the United States cancer population and thus has sufficient power to address the relation between HHT diagnosis and survival outcome. The results, based on over 540,520 cancer patients and 127 instances of HHT diagnosis, relates an endoglin-deficient state to cancer outcomes, providing support for the hypothesis that endoglin expression in the stroma, versus the tumor, is a determinant of cancer survival, and suggests which high prevalence cancers might most benefit from endoglin-suppressive anti-endoglin antibody therapies (4).
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